SRx Health Solutions Acquires 4.99% of Smartkem, Inc. (NASDAQ: SMTK)

Rhea-AI Summary

SRx Health Solutions (NYSE American: SRXH) and EMJ Crypto Technologies (EMJX) announced the acquisition of 4.99% of Smartkem (NASDAQ: SMTK) via a shelf takedown. The company also bought convertible preferred securities in a non-brokered private placement.

SRx has a definitive merger agreement with EMJX and has filed a Form S-4 registration statement with the SEC for stock to be issued in the proposed transaction. Investors are urged to read the Registration Statement and Information Statement/Prospectus when available. The communication does not constitute an offer or solicitation to buy or sell securities.

Positive

• Acquired 4.99% equity stake in Smartkem (NASDAQ: SMTK) via shelf takedown
• Purchased additional exposure through Smartkem convertible preferred securities in private placement
• Definitive merger agreement in place between SRx Health Solutions and EMJ Crypto Technologies
• Form S-4 registration statement filed with SEC for stock issuance in proposed merger

Negative

• None.

News Market Reaction – SRXH

+3.31%

1 alert

+3.31% Session close to close

$71.54M Market Cap

0.0x Rel. Volume

In the Jun 8 session, SRXH gained 3.31%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement adds a 4.99% equity stake in Smartkem, plus convertible preferred securities, to S...

Analysis

This announcement adds a 4.99% equity stake in Smartkem, plus convertible preferred securities, to SRx Health’s expanding portfolio alongside its pending all‑stock EMJX transaction. Historically, acquisition news has produced both strong gains and notable declines, underscoring execution and capital‑structure risk. Investors may watch how this position fits with prior moves into digital assets, uranium royalties, and other thematic bets, as well as future disclosures on terms, integration, and balance‑sheet impact.

Key Figures

Smartkem stake: 4.99%

1 metrics

Smartkem stake 4.99% Equity interest in Smartkem, Inc. acquired via shelf take down

Previous Acquisition Reports

3 past events · Latest: Apr 16 (Positive)

Same Type Pattern 3 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 16	Portfolio acquisitions	Positive	+6.4%	Disclosed S-4 filing plus increased stakes in Compass and Opendoor.
Dec 16	EMJX acquisition deal	Positive	+23.8%	Definitive agreement to acquire EMJX with planned combined platform.
Aug 18	Royal Uranium LOI	Positive	-16.0%	LOI to acquire 100% of Royal Uranium’s assets and royalties.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior acquisition‑type announcements have produced mixed reactions, with two positive moves and one sharp decline.

Recent Company History

Over the past year, SRx Health has repeatedly used acquisitions and portfolio shifts as strategic tools. On Aug 18, 2025, it signed a letter of intent to acquire 100% of Royal Uranium’s assets, leading to a -16.02% move. A definitive deal to acquire EMJ Crypto Technologies in Dec 2025 drove a 23.78% gain. In Apr 2026, disclosure of increased stakes in Compass and Opendoor produced a 6.42% rise. Today’s Smartkem stake continues this acquisition‑driven capital allocation pattern.

Key Terms

shelf take down, convertible preferred securities, non-brokered private placement, registration statement on form s-4, +4 more

8 terms

shelf take down financial

"a leader in advanced materials, through a shelf take down."

A shelf takedown is when a company actually issues and sells securities that it previously registered and held “on the shelf” for future use. Think of it like a store owner taking a pre-approved product down from the shelf to put it up for sale: it gives the company quick access to cash but can dilute existing shareholders or change debt levels, so investors watch takedowns for their impact on share value and company finances.

convertible preferred securities financial

"purchased convertible preferred securities through a non-brokered private placement."

Convertible preferred securities are a hybrid investment that pays a regular dividend like a bond but can be exchanged for a company’s common shares at a set rate. They matter to investors because they offer downside protection and steady income while preserving the option to share in upside if the stock rises, but conversion can dilute existing shareholders and changes risk/return dynamics.

non-brokered private placement financial

"securities through a non-brokered private placement."

A non-brokered private placement is when a company raises money by selling securities (such as shares or bonds) directly to a small group of chosen investors without using a broker or dealer as a middleman. For investors it matters because it can provide faster, lower-cost access to new investment opportunities but may bring higher risk, less liquidity and potential dilution of existing holdings compared with public offerings.

registration statement on form s-4 regulatory

"filed with the SEC a Registration Statement on Form S-4 (the "Registration Statement")"

A registration statement on Form S-4 is a formal filing with the U.S. Securities and Exchange Commission used when a company issues shares or other securities as part of a merger, acquisition, exchange offer or similar corporate deal. It bundles the transaction terms, financial statements, risk factors and shareholder vote materials so investors can assess the deal; think of it as a detailed prospectus or buyer’s packet that explains what you would own and how the deal could change your stake.

information statement/prospectus regulatory

"The Registration Statement includes an information statement of the Company and a prospectus..."

A prospectus or information statement is a formal document that lays out key facts about a company, an offer of securities, or a proposed corporate action so investors can make informed choices. Think of it as a product label that explains what is being sold, the risks, the company’s finances and how proceeds will be used; investors rely on it to compare options and judge whether the potential reward justifies the risk.

prospectus regulatory

"No offer of securities shall be made except by means of a prospectus meeting the requirements"

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

securities act regulatory

"requirements of Section 10 of the Securities Act, or in a transaction exempt"

A securities act is a law that governs the offering, sale and disclosure of stocks, bonds and other investment products to the public. It requires companies to provide clear, truthful information—like a product label for an investment—so buyers can understand risks and value before they invest. For investors, these rules reduce fraud, promote transparency, and help ensure fair access to market information.

private placement financial

"convertible preferred securities through a non-brokered private placement."

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NORTH PALM BEACH, Fla., June 08, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") and EMJ Crypto Technologies ("EMJX"), a digital-asset treasury operating platform with which the Company has entered into a definitive merger agreement, today announced acquiring 4.99% of Smartkem, Inc. (NASDAQ: SMTK), a leader in advanced materials, through a shelf take down. In conjunction with the 4.99% of equity, the Company has also purchased convertible preferred securities through a non-brokered private placement.

Additional Information and Where to Find It
In connection with the proposed transaction between the Company has filed with the SEC a Registration Statement on Form S-4 (the "Registration Statement") to register the common stock to be issued in connection with the proposed transaction. The Registration Statement includes an information statement of the Company and a prospectus of the Company (the "Information Statement/Prospectus"), and each of EMJX and the Company may file with the SEC other relevant documents concerning the proposed transaction. After the Registration Statement is declared effective, the definitive Information Statement/Prospectus will be sent to the stockholders This is not a substitute for the Registration Statement, the Information Statement/Prospectus or any other relevant documents that EMJX or the Company has filed or will file with the SEC. BEFORE MAKING ANY INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO CAREFULLY AND ENTIRELY READ THE REGISTRATION STATEMENT AND INFORMATION STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, IF AND WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT EMJX, THE COMPANY, THE PROPOSED TRANSACTION, AND RELATED MATTERS. A copy of the Registration Statement, Information Statement/Prospectus, as well as other relevant documents filed by EMJX and the Company with the SEC, may be obtained free of charge, when they become available, at the SEC's website at www.sec.gov. The information on EMJX's or the Company's respective websites is not, and shall not be deemed to be, a part of this communication or incorporated into other filings either company makes with the SEC.

No Offer or Solicitation
This communication is for informational purposes only and is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy or sell any securities or the solicitation of any proxy, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or in a transaction exempt from the registration requirements of the Securities Act.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "expect," "intend," "aim," "plan," "may," "could," "target," and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, but are not limited to, the ability to complete the proposed transaction, shareholder approvals, market conditions, regulatory considerations, and other risks described in the Company's filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date made, and the Company undertakes no obligation to update them, except as required by law.

Company Contact
SRx Health Solutions, Inc.
Kent Cunningham, Chief Executive Officer

Investor Relations Contact
KCSA Strategic Communications
Valter Pinto, Managing Director
212-896-1254
valter@kcsa.com

FAQ

What Smartkem (NASDAQ: SMTK) stake did SRx Health Solutions (NYSE American: SRXH) announce on June 8, 2026?

SRx Health Solutions announced acquiring 4.99% of Smartkem’s equity on June 8, 2026. According to the company, the position was established via a shelf takedown, alongside purchasing Smartkem convertible preferred securities in a non-brokered private placement for additional exposure.

How much of Smartkem stock does SRx Health Solutions (SRXH) own after the June 2026 transaction?

SRx Health Solutions reports owning 4.99% of Smartkem’s equity following the June 2026 deal. According to the company, this ownership was obtained through a shelf takedown and is complemented by privately placed Smartkem convertible preferred securities purchased in a non-brokered transaction.

What role does EMJ Crypto Technologies (EMJX) play in SRx Health Solutions’ Smartkem (SMTK) investment?

EMJ Crypto Technologies is SRx Health Solutions’ merger partner in a definitive agreement. According to the company, SRx and EMJX jointly announced acquiring 4.99% of Smartkem and related convertible preferred securities, linking the Smartkem investment to their broader proposed merger transaction.

What is the Form S-4 filed by SRx Health Solutions (SRXH) regarding the EMJ Crypto merger?

Form S-4 is a registration statement for stock SRx will issue in the proposed EMJX merger. According to the company, it includes an Information Statement/Prospectus for shareholders, who are urged to read it carefully once the SEC declares it effective.

Where can SRx Health Solutions (SRXH) and EMJ Crypto investors find SEC documents about the proposed transaction?

Investors can access the Registration Statement and related filings free on the SEC’s website at www.sec.gov. According to the company, these documents include the Form S-4 and Information Statement/Prospectus, which will contain important information about SRx, EMJX and the proposed merger.

Does SRx Health Solutions’ June 8, 2026 announcement constitute an offer to buy or sell SRXH or SMTK securities?

The announcement does not constitute an offer to buy or sell any securities. According to the company, any offer must be made only by a prospectus meeting Securities Act requirements or through a transaction exempt from registration, and only where legally permitted.